Previous Next


№3' 2016


International Medical Journal, Vol. 22., Iss. 3, 2016, P. 55−58.


Mikhanovskyi O. A., Yuliia Vladimirovna Kharchenko, Kruhova I. M., Danyliuk S. V., Shchyt N. N., Fedorenko N. V., Marina Anatolevna Teplova

S. P. Grigoriev Institute for Medical Radiology, Kharkiv, Ukraine

At present a new direction, the use of molecular biological markers (MBM) to predict the course of the malignant process and choose optimal therapy, have been actively developed in oncology. Determining MBM can provide additional information on the biological behavior of the tumor: the rate of its growth, its ability of invasion and metastasis, resistance to chemotherapy. Most attention is paid to the study of MBM, which characterize apoptosis, cell proliferation and angiogenesis, which include p53, Bcl−2, Ki 67 and VEGF. Molecular biological markers of ovarian tumors were studied in patients with stage 3−4 ovarian cancer (T3cNxM0−1). In the majority of patients the treatment was started with neoadjuvant chemotherapy (NHT) followed by surgery. The rest had surgical treatment followed by adjuvant chemotherapy was performed. The investigation revealed that expression of mt p53 depended on the extent of malignancy, it increased with the degree of mutation process. The majority of patients with recurrent ovarian cancer showed a high expression of mt p53 in combination with the absence of Bcl−2 expression. This was particularly evident in the patients over 50 years. NCT affected expression of Ki−67 and Bcl−2 in ovarian cancer patients, which can be used to assess sensitivity of the individual tumors to chemotherapy. The relationship between VEGF expression and a high level of tumor marker CA 125 indicates a high metastatic tumor activity, which is a negative factor in ovarian cancer prognosis. The findings of the investigation can be used to form the groups of patients at higher risk of recurrence and metastases.

Key words: ovarian cancer, molecular−biological markers, combination treatment.

Go on Top